報價延遲最少15分鐘:2025/05/16 16:26 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.42 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.34/-0.63
|
|
企業價值
8.64M
|
| 資產負債 |
|
每股賬面淨值
-0.53
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/16 16:26 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC). |